Minireviews
Copyright ©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 1000-1008
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1000
Table 1 Outcomes in four consensus molecular subtype profiles
Ref.
n
Outcomes
CMS1, mean (95%CI)
CMS2, mean (95%CI)
CMS3, mean (95%CI)
CMS4, mean (95%CI)
Stages I-IV
Purcell et al[39], 20192575-yr OS (%)63.7 (51.1-79.4)64.4 (56.6-73.4)52.8 (37.1-75.1)42.8 (23.8-76.8)
5-yr PFS (%)61.2 (48.8-76.8)59.8 (51.8-68.9)52.7 (47.5-74.0)38.8 (21.0-71.9)
Guinney et al[8], 201521295-yr OS (%)74 (70-75)77 (74-80)75 (70-80)62 (58-66)
5-yr DFS (%)75 (70-80)73 (70-77)73 (68-80)60 (55-65)
Stage II
Shinto et al[36], 20202325-yr DFS (%)10085.592.373
Stage IV
Borelli et al[43], 2021426OS (mo)13.7 (6.1-27.9)27.0 (23.9-30.1)18.3 (16.1-24.0)26.2 (21.4-29.9)
PFS (mo)5.4 (3.8-9.9)12.9 (11.0-14.3)8.3 (7.4-10.1)10.7 (9.8-13.1)
Stintzing et al[20], 2019438OS (mo)15.9 (11.0-20.8)29.0 (26.7-31.4)18.6 (15.4-21.7)24.8 (22.6-27.1)
PFS (mo)8.2 (6.7-9.6)11.7 (10.8-12.6)8.5 (6.8-10.3)9.6 (8.6-10.6)
Lenz et al[16], 2019581OS (mo)15.0 (11.7-22.4)40.3 (36.1-43.1)24.3 (16.4-29.0)31.4 (26.3-36.9)
PFS (mo)7.1 (5.7-8.6)13.4 (12.8-15.4)8.7 (7.2-9.8)11.0 (9.7-12.0)
Mooi et al[41], 2018237OS (mo)8.8 (6.5-16.0)24.2 (19.1-27.4)17.6 (11.3-24.6)21.4 (15.8-23.1)
PFS (mo)No statistical differences in this cohort
Okita et al[42], 2018193OS (mo)21.4 (13.3-35.5)48.1 (34.8-65.6)38.7 (30.6-45.6)44.0 (33.0-50.5)